IP Library Granted Patent US 11,660,318
Granted Patent B2
US 11,660,318 · App. 16/265,819 · Granted May 30, 2023

Use of adipose tissue-derived stromal stem cells in treating fistula

Inventors: María Gema Fernández Miguel (Tres Cantos-Madrid, ES); Manuel Ángel González De La Pena (Tres Cantos-Madrid, ES); Rosa Ana García Castro (Tres Cantos-Madrid, ES); Mariano García Arranz (Cantoblanco-Madrid, ES); Damián García Olmo (Cantoblanco-Madrid, ES)
Assignee: Takeda Pharmaceutical Company Limited
A61K35/35A61B17/1659A61B17/32A61K45/06A61L24/0015A61L24/106A61L27/3604A61L27/3834A61L27/3839A61L27/3869A61L27/3895C12N5/0667A61B2017/320008A61K35/12A61L2300/64C12N2509/00C12N2510/00C12N2533/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,660,318
App. No.
16/265,819
Granted
May 30, 2023
Kind
B2
Abstract

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Claims (18)

1. A method of treating a fistula in a subject comprising injecting into the walls of the fistula tract at one or more sites a first composition comprising at least 10×10 6 adipose tissue-derived stromal stem cells.

2. The method of claim 1 , wherein the first composition comprises at least 20×10 6 adipose tissue derived stromal stem cells.

3. The method of claim 1 , wherein said adipose tissue-derived stromal stem cells were passaged at least four times.

4. The method of claim 1 , wherein the concentration of the adipose tissue-derived stromal stem cells in the first composition is at least 5×10 6 cells/mL.

5. The method of claim 1 , wherein the adipose tissue-derived stromal stem cells are allogeneic to the subject.

6. The method of claim 1 , wherein at least 50% of the cells in the population express the CD44 marker.

7. The method of claim 1 , wherein the fistula is selected from the group consisting of an anorectal fistula, enteroenteral fistula, enterocutaneous fistula, vesicovaginal fistula, fistula-in-ano, fecal fistula, arteriovenous fistula, biliary fistula, cervical fistula, craniosinus fistula, enterovaginal, gastric fistula, metroperitoneal fistula perilymph, pulmonary arteriovenous fistula, umbilical fistula, and tracheoesophageal fistula.

8. The method of claim 1 , further comprising administering a therapeutic agent to said subject.

9. The method of claim 8 , wherein said therapeutic agent is administered locally to the fistula.

10. The method of claim 8 , wherein said therapeutic agent is administered systemically to said subject.

11. The method of claim 8 , wherein said therapeutic agent is selected from the group consisting of an anti-inflammatory agent, an immunosuppressive agent, a biological agent, an antibiotic and an antidiarrheal agent.

12. The method of claim 1 , further comprising

(i) deep scraping of at least one fistula track

(ii) closing the internal hole of the scraped track with a suture

(iii) delivering a second composition comprising at least 10×10 6 adipose tissue-derived stromal stem cells to the closed sutured internal hole, wherein delivery of the first composition occurs before step (i), after step (iii), between step (i) and (ii), or between step (ii) and (iii).

13. The method of claim 12 , further comprising deep scraping of the fistula prior to delivering the first composition and filling said fistula with an adhesive before, during or after delivering the second composition.

14. The method of claim 13 , wherein the second composition is mixed with the adhesive before delivering the second composition.

15. The method of claim 13 , wherein said adhesive is a fibrin glue or gel.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2023
From: UNIVERSIDAD AUTÓNOMA DE MADRID
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 062502/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: TIGENIX, S.A.U.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 060516/0532 →
CHANGE OF NAME Recorded Jan 23, 2020
From: CELLERIX, S.A.U.
To: TIGENIX, S.A.U.
Reel/Frame 051689/0390 →
CONVERSION Recorded Nov 7, 2019
From: CELLERIX, S.L.
To: CELLERIX, S.A.
Reel/Frame 050966/0978 →
REORGANIZATION Recorded Nov 7, 2019
From: CELLERIX, S.A.
To: CELLERIX, S.A.U.
Reel/Frame 050966/0935 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2019
From: GARCÍA ARRANZ, MARIANO; GARCÍA OLMO, DAMIÁN
To: UNIVERSIDAD AUTÓNOMA DE MADRID
Reel/Frame 050953/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2019
From: FERNÁNDEZ MIGUEL, MARÍA GEMA; GONZÁLEZ DE LA PEÑA, MANUEL ÁNGEL; GARCÍA CASTRO, ROSA ANA
To: CELLERIX, S.L.
Reel/Frame 050953/0490 →
Continuity (5)
Continuation 15464149 · Mar 20, 2017
Continuation 14538681 · Nov 11, 2014
Continuation 11993859
Continuation 11167061 · Jun 24, 2005
Related Publication 20190269737A1 · Sep 5, 2019